Reperfusion of very low cerebral blood volume lesion predicts parenchymal hematoma after endovascular therapy.

Details

Serval ID
serval:BIB_1847F281C5F9
Type
Article: article from journal or magazin.
Collection
Publications
Title
Reperfusion of very low cerebral blood volume lesion predicts parenchymal hematoma after endovascular therapy.
Journal
Stroke; A Journal of Cerebral Circulation
Author(s)
Mishra N.K., Christensen S., Wouters A., Campbell B.C., Straka M., Mlynash M., Kemp S., Cereda C.W., Bammer R., Marks M.P., Albers G.W., Lansberg M.G.
Working group(s)
DEFUSE 2 Investigators
ISSN
1524-4628 (Electronic)
ISSN-L
0039-2499
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
46
Number
5
Pages
1245-1249
Language
english
Abstract
BACKGROUND AND PURPOSE: Ischemic stroke patients with regional very low cerebral blood volume (VLCBV) on baseline imaging have increased risk of parenchymal hemorrhage (PH) after intravenous alteplase-induced reperfusion. We developed a method for automated detection of VLCBV and examined whether patients with reperfused-VLCBV are at increased risk of PH after endovascular reperfusion therapy.
METHODS: Receiver operating characteristic analysis was performed to optimize a relative CBV threshold associated with PH in patients from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) study. Regional reperfused-VLCBV was defined as regions with low relative CBV on baseline imaging that demonstrated normal perfusion (Tmax <6 s) on coregistered early follow-up magnetic resonance imaging. The association between VLCBV, regional reperfused-VLCBV and PH was assessed in univariate and multivariate analyses.
RESULTS: In 91 patients, the greatest area under the curve for predicting PH occurred at an relative CBV threshold of <0.42 (area under the curve, 0.77). At this threshold, VLCBV lesion volume ≥3.55 mL optimally predicted PH with 94% sensitivity and 63% specificity. Reperfused-VLCBV lesion volume was more specific (0.74) and equally sensitive (0.94). In total, 18 patients developed PH, of whom 17 presented with VLCBV (39% versus 2%; P=0.001), all of them had regional reperfusion (47% versus 0%; P=0.01), and 71% received intravenous alteplase. VLCBV lesion (odds ratio, 33) and bridging with intravenous alteplase (odds ratio, 3.8) were independently associated with PH. In a separate model, reperfused-VLCBV remained the single independent predictor of PH (odds ratio, 53).
CONCLUSIONS: These results suggest that VLCBV can be used for risk stratification of patients scheduled to undergo endovascular therapy in trials and routine clinical practice.
Keywords
Aged, Aged, 80 and over, Brain Ischemia/surgery, Cerebral Hemorrhage/physiopathology, Cerebral Hemorrhage/surgery, Cerebrovascular Circulation, Endovascular Procedures/adverse effects, Female, Fibrinolytic Agents/therapeutic use, Humans, Hypovolemia/therapy, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies, Reperfusion/methods, Risk Assessment, Stroke/surgery, Tissue Plasminogen Activator/therapeutic use, Treatment Outcome
Pubmed
Create date
16/03/2016 19:08
Last modification date
20/08/2019 13:48
Usage data